Literature DB >> 11290552

Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

Y Matsuoka1, M Picciano, B Malester, J LaFrancois, C Zehr, J M Daeschner, J A Olschowka, M I Fonseca, M K O'Banion, A J Tenner, C A Lemere, K Duff.   

Abstract

Mutations in the amyloid precursor protein (APP) and presenilin-1 and -2 genes (PS-1, -2) cause Alzheimer's disease (AD). Mice carrying both mutant genes (PS/APP) develop AD-like deposits composed of beta-amyloid (Abeta) at an early age. In this study, we have examined how Abeta deposition is associated with immune responses. Both fibrillar and nonfibrillar Abeta (diffuse) deposits were visible in the frontal cortex by 3 months, and the amyloid load increased dramatically with age. The number of fibrillar Abeta deposits increased up to the oldest age studied (2.5 years old), whereas there were less marked changes in the number of diffuse deposits in mice over 1 year old. Activated microglia and astrocytes increased synchronously with amyloid burden and were, in general, closely associated with deposits. Cyclooxygenase-2, an inflammatory response molecule involved in the prostaglandin pathway, was up-regulated in astrocytes associated with some fibrillar deposits. Complement component 1q, an immune response component, strongly colocalized with fibrillar Abeta, but was also up-regulated in some plaque-associated microglia. These results show: i) an increasing proportion of amyloid is composed of fibrillar Abeta in the aging PS/APP mouse brain; ii) microglia and astrocytes are activated by both fibrillar and diffuse Abeta; and iii) cyclooxygenase-2 and complement component 1q levels increase in response to the formation of fibrillar Abeta in PS/APP mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290552      PMCID: PMC1891893          DOI: 10.1016/S0002-9440(10)64085-0

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  The presence of isoaspartic acid in beta-amyloid plaques indicates plaque age.

Authors:  M I Fonseca; E Head; P Velazquez; C W Cotman; A J Tenner
Journal:  Exp Neurol       Date:  1999-06       Impact factor: 5.330

Review 2.  Inflammatory mechanisms in Alzheimer's disease: implications for therapy.

Authors:  P S Aisen; K L Davis
Journal:  Am J Psychiatry       Date:  1994-08       Impact factor: 18.112

3.  The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.

Authors:  S D Webster; A J Tenner; T L Poulos; D H Cribbs
Journal:  Neurobiol Aging       Date:  1999 May-Jun       Impact factor: 4.673

4.  Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss.

Authors:  A Takeuchi; M C Irizarry; K Duff; T C Saido; K Hsiao Ashe; M Hasegawa; D M Mann; B T Hyman; T Iwatsubo
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease.

Authors:  S Itagaki; P L McGeer; H Akiyama; S Zhu; D Selkoe
Journal:  J Neuroimmunol       Date:  1989-10       Impact factor: 3.478

6.  Mouse strains with typical mammalian levels of complement activity.

Authors:  G L Ong; M J Mattes
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

Review 7.  Tau protein and the neurofibrillary pathology of Alzheimer's disease.

Authors:  M Goedert
Journal:  Trends Neurosci       Date:  1993-11       Impact factor: 13.837

8.  Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids.

Authors:  K Yamagata; K I Andreasson; W E Kaufmann; C A Barnes; P F Worley
Journal:  Neuron       Date:  1993-08       Impact factor: 17.173

9.  Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

Authors:  T C Saido; T Iwatsubo; D M Mann; H Shimada; Y Ihara; S Kawashima
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

Review 10.  Microglia in degenerative neurological disease.

Authors:  P L McGeer; T Kawamata; D G Walker; H Akiyama; I Tooyama; E G McGeer
Journal:  Glia       Date:  1993-01       Impact factor: 7.452

View more
  80 in total

Review 1.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

Review 2.  The role of inflammatory processes in Alzheimer's disease.

Authors:  G Joseph Broussard; Jennifer Mytar; Rung-chi Li; Gloria J Klapstein
Journal:  Inflammopharmacology       Date:  2012-04-26       Impact factor: 4.473

3.  Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch.

Authors:  Anahit Ghochikyan; Mikayel Mkrtichyan; Irina Petrushina; Nina Movsesyan; Adrine Karapetyan; David H Cribbs; Michael G Agadjanyan
Journal:  Vaccine       Date:  2005-12-05       Impact factor: 3.641

4.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.

Authors:  Syaun Sung; Hengxuan Yang; Kunihiro Uryu; Edward B Lee; Lei Zhao; Diana Shineman; John Q Trojanowski; Virginia M-Y Lee; Domenico Praticò
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 5.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

6.  Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.

Authors:  Qiaoqiao Shi; Saba Chowdhury; Rong Ma; Kevin X Le; Soyon Hong; Barbara J Caldarone; Beth Stevens; Cynthia A Lemere
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

7.  Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents.

Authors:  Sang-Pil Lee; Maria F Falangola; Ralph A Nixon; Karen Duff; Joseph A Helpern
Journal:  Magn Reson Med       Date:  2004-09       Impact factor: 4.668

8.  Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Authors:  Marcel Maier; Ying Peng; Liying Jiang; Timothy J Seabrook; Michael C Carroll; Cynthia A Lemere
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

Review 9.  Glial cell dysregulation: a new perspective on Alzheimer disease.

Authors:  Rommy von Bernhardi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

10.  Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.

Authors:  Yun Ding; Aimin Qiao; Ziqing Wang; J Shawn Goodwin; Eun-Sook Lee; Michelle L Block; Matthew Allsbrook; Michael P McDonald; Guo-Huang Fan
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.